Low-Dose Naltrexone Dosage, half-life & reference guide
Also known as LDN · Naltrexone (low dose) · Low dose naltrexone
Reviewed Evidence: EmergingPublished by PepVault
A small daily dose of naltrexone, a drug approved at 50 mg for alcohol and opioid dependence. At 1–6 mg it is thought to reset the body's endorphin system and calm inflammation, and it is widely used for fibromyalgia, long COVID and autoimmune conditions. In placebo-controlled fibromyalgia trials, though, it did no better than placebo for pain, and long-COVID evidence has no control groups yet.
- Studied range
- 1–6 mg
- How often
- Daily
- Evidence
- ●
●●Emerging - Route
- Oral
Studied in research — not a recommendation. Naltrexone is FDA-approved at 50 mg for alcohol dependence and opioid blockade; the low doses are off-label.
How it works.
Naltrexone blocks opioid receptors; at the approved 50 mg it treats alcohol and opioid dependence. Low-dose naltrexone uses about a tenth of that or less, on a different theory: that a brief, partial block nudges the body's own endorphin system and calms immune cells in the brain, easing pain, fatigue and inflammation. It is popular for fibromyalgia, long COVID and autoimmune conditions. The placebo-controlled trials tell a cooler story: in three fibromyalgia trials from 2023 to 2026, LDN was no better than placebo for pain. For long COVID, no randomized trial had reported by May 2026.
Commonly reported: Vivid dreams in the first weeks; some feel less pain and fatigue.
Your report
Taken Low-Dose Naltrexone? What did you notice?
One tap to start. About 30 seconds, no account.

Week by week.
What to expect in the first 8 weeks
- Onset
- Weeks (reported)
- Peak effect
- Not established
- Duration
- Trials ran 12 weeks to 12 months
Day 1–14Community
Vivid dreams are the common first sign
The idea behind LDN is that a short nightly block of opioid receptors prompts the body to make more of its own endorphins. Commonly reported: vivid dreams in the first weeks, which tend to fade. In the trials, side effects were about as common as on placebo.
The science
Due Bruun 2024 (FINAL): adverse events 41 of 49 (84%) on 6 mg vs 43 of 50 (86%) on placebo; discontinuations 8% vs 6%. INNOVA (2026): adverse events mostly mild and transient. The endorphin-rebound and glial theories are hypotheses; the label describes naltrexone as a pure opioid antagonist.
Sources- Due Bruun et al. (FINAL) (2024)
- Rodríguez-Freire et al. (INNOVA) (2026)
Updated Nov 2026
Day 1–60Clinical
The one thing it must not meet
Naltrexone blocks opioids, at low doses too. That matters for anyone who needs an opioid painkiller, for example after surgery or an injury, or who takes methadone or buprenorphine: the label rules those combinations out. A clinician can plan a pause around a procedure.
The science
Naltrexone tablets label (DailyMed, Nov 16, 2026): contraindicated in patients receiving opioid analgesics, currently dependent on opioids including methadone or buprenorphine, or in acute withdrawal; precipitates withdrawal in opioid-dependent people; attempts to overcome the blockade risk overdose. Hepatotoxicity warning at the approved dose; exposure 5- to 10-fold higher in cirrhosis.
Sources- FDA label, naltrexone tablets (2026)
Updated Nov 2026
Day 14–90RCT
Fibromyalgia trials: no better than placebo
Fibromyalgia is where LDN was tested hardest. In three placebo-controlled trials from Denmark and Spain, pain eased a little on LDN, but about as much on placebo. One trial saw a possible benefit for memory problems, worth a future study.
The science
Due Bruun 2024 (Lancet Rheumatol, NCT04270877): 99 women, 6 mg or placebo for 12 weeks; pain −1.3 vs −0.9 (difference −0.34, 95% CI −0.95 to 0.27; p = 0.27). Rodríguez-Freire 2026 (Eur J Pain): 98 women, 4.5 mg, pain at 3 months −0.33 vs −0.64 (p = 0.236). Bested 2023 (Pain Rep): 58 patients, crossover, 4.5 mg; no clinically relevant analgesic effect. Ologunowa 2025: 8 trials, pain vs placebo SMD −0.50 (−1.19 to 0.19).
Sources- Due Bruun et al. (FINAL) (2024)
- Rodríguez-Freire et al. (2026)
- Bested et al. (2023)
- Ologunowa et al. (2025)
Updated Nov 2026
Any dayRCT
What LDN is built on
LDN rests on a plausible theory, strong word of mouth and uncontrolled studies. When tested against placebo in fibromyalgia, it has not won, and long-COVID studies so far have no control group. It has not been tested for aging or lifespan.
The science
Byambasuren 2026 (BMJ Open, searched to May 5, 2026): no RCTs of LDN in long COVID; four pre-post studies (155 people, 1–6 mg a day) reported improvements in fatigue (Hedges' g −0.74), brain fog, sleep and pain without a control group. Fibromyalgia RCTs: Due Bruun 2024, Rodríguez-Freire 2026, Bested 2023, all negative on pain. Not tested by the NIA ITP.
Sources- Byambasuren et al. (2026)
- Due Bruun et al. (FINAL) (2024)
Updated Nov 2026
With BPC-157, Thymosin Alpha-1 and KPVCommunity
An inflammation stack with untested pieces
LDN often sits in community stacks with BPC-157, KPV or thymosin alpha-1 aimed at gut or immune inflammation. No study has tested LDN with any peptide, and LDN itself has not beaten placebo where it was tested hardest.
The science
No trial combines LDN with a peptide. LDN's placebo-controlled evidence: the fibromyalgia RCTs above. Each peptide's own evidence is in its library entry.
Sources- Due Bruun et al. (FINAL) (2024)
Updated Nov 2026
Day 1 is the day you start it.
The naltrexone FDA label (DailyMed, Nov 2026); three placebo-controlled fibromyalgia RCTs and a meta-analysis; a long-COVID review with only uncontrolled studies.
Preliminary research
A typical run.
Run notes
- Cycle
- Taken once a day in the trials, 12 weeks (FINAL) to 12 months (INNOVA).Community practice — opinions vary. Not a clinical recommendation.
- Timing
- The trials gave it once daily. Many in the community take it at bedtime, which is when vivid dreams are most often reported.
- Route
- Oral
- Stacks
- BPC-157, Thymosin Alpha-1, KPV
Safety.
Common side effects
- Vivid dreams or sleep changes (commonly reported)
- Nausea or headache (the label's most common at 50 mg)
- Side effects about as common as on placebo in the low-dose trials
Interactions
It blocks opioid medicines (painkillers, cough medicines containing opioids, methadone, buprenorphine), per the label; trying to overcome the block with more opioid risks overdose. Discuss every medication with your clinician.
Safety notes
Naltrexone is a prescription drug; the approved tablet is 50 mg for alcohol and opioid dependence, and the 1–6 mg doses are off-label. Its label rules it out for anyone taking opioid painkillers or dependent on opioids (including methadone or buprenorphine), because it blocks them and can bring on withdrawal, and warns of liver injury at the approved dose, with much higher exposure in cirrhosis. In the low-dose fibromyalgia trials, adverse events were about as frequent as on placebo (84% vs 86% in one). Discuss with your clinician, who can plan around any opioid use or surgery.
Goes with.
One question at a time.
Questions people ask.
What is Low-Dose Naltrexone?
A small daily dose of naltrexone, a drug approved at 50 mg for alcohol and opioid dependence. At 1–6 mg it is thought to reset the body's endorphin system and calm inflammation, and it is widely used for fibromyalgia, long COVID and autoimmune conditions. In placebo-controlled fibromyalgia trials, though, it did no better than placebo for pain, and long-COVID evidence has no control groups yet.
How is Low-Dose Naltrexone dosed in research?
The research range for Low-Dose Naltrexone is 1–6 mg, daily. Studied in research — not a recommendation. Naltrexone is FDA-approved at 50 mg for alcohol dependence and opioid blockade; the low doses are off-label.
How long does Low-Dose Naltrexone last?
The half-life of Low-Dose Naltrexone is not a single number for low doses: naltrexone and its active metabolite 6-beta-naltrexol are cleared by the liver and kidneys, and oral bioavailability is 5–40% (FDA label).
What do people report on Low-Dose Naltrexone?
Commonly reported on Low-Dose Naltrexone: vivid dreams in the first weeks; some feel less pain and fatigue.
Is Low-Dose Naltrexone safe?
The research basis for Low-Dose Naltrexone is emerging: primarily preclinical / limited human data. Common side effects in the library: vivid dreams or sleep changes (commonly reported), nausea or headache (the label's most common at 50 mg) and side effects about as common as on placebo in the low-dose trials.
What does Low-Dose Naltrexone stack with?
Common stacks for Low-Dose Naltrexone: BPC-157, Thymosin Alpha-1 and KPV.
Research.
Reference.
- Cadence
Daily
- Half-life
Not a single number for low doses: naltrexone and its active metabolite 6-beta-naltrexol are cleared by the liver and kidneys, and oral bioavailability is 5–40% (FDA label)
- Research basis
●
●●EmergingPrimarily preclinical / limited human data
Reviewed How we check the library
